Not recruiting
Diffuse large B-cell lymphoma+5
Not recruitingInvestigationalNo placebo
Study on MB-CART19.1 for Patients with Relapsed or Refractory CD19 Positive B Cell Malignancies
InvestigationalNo placebo
- Disease:Diffuse large B-cell lymphomaMantle cell lymphoma+4
- Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
Countries:
Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
- Sponsor:Miltenyi Biomedicine GmbH
